Back to Journals » Lung Cancer: Targets and Therapy » Volume 12 » default
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (183)
- Volume 15, 2024 (11)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 12, 2021
The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers
Vokes NI, Zhang J
Lung Cancer: Targets and Therapy 2021, 12:139-149
Published Date: 2 December 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:133-138
Published Date: 2 December 2021
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Fitzpatrick O, Naidoo J
Lung Cancer: Targets and Therapy 2021, 12:123-131
Published Date: 2 November 2021
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:115-122
Published Date: 7 October 2021
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:103-114
Published Date: 7 October 2021
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H
Lung Cancer: Targets and Therapy 2021, 12:93-102
Published Date: 30 August 2021
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer
Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R
Lung Cancer: Targets and Therapy 2021, 12:81-92
Published Date: 16 August 2021
Targeting AXL in NSCLC
Zaman A, Bivona TG
Lung Cancer: Targets and Therapy 2021, 12:67-79
Published Date: 10 August 2021
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Zhang SS, Zhu VW
Lung Cancer: Targets and Therapy 2021, 12:61-65
Published Date: 12 July 2021
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Shukla N, Hanna N
Lung Cancer: Targets and Therapy 2021, 12:51-60
Published Date: 28 June 2021
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
Fujino T, Suda K, Mitsudomi T
Lung Cancer: Targets and Therapy 2021, 12:35-50
Published Date: 20 May 2021
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Giustini N, Bazhenova L
Lung Cancer: Targets and Therapy 2021, 12:21-34
Published Date: 25 March 2021
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW
Lung Cancer: Targets and Therapy 2021, 12:11-20
Published Date: 18 March 2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Yu D, Zhao W, Vallega KA, Sun SY
Lung Cancer: Targets and Therapy 2021, 12:1-10
Published Date: 5 February 2021